In a retrospective analysis of the Optum database, overactive bladder patients treated with mirabegron bladder patients persisted longer with treatment than patients treated with tolterodine, and had reduced resource utilization and costs.
Gilbert N. Muma, PhD
Advertisement
Articles by Gilbert N. Muma, PhD
Advertisement
Latest Updated Articles
- Persistence With Mirabegron Versus Tolterodine in Patients With Overactive Bladder
Published: April 19th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Common Virus May Hold New Clues to Lupus
2
Managing Safety and Supportive Care With Pluvicto: Insights From the PSMAddition Trial
3
SHR-A1811 Plus Pertuzumab Improves Survival in HER2-Positive Metastatic Breast Cancer
4
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
5
